The onset of Alzheimer’s symptoms is different for every patient, but researchers are hoping their ‘clock’ method could one day predict when they will develop.
Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer's disease, Canada's Drug Agency says in its draft recommendation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results